The influence of cardiovascular and antiinflammatory drugs on thiazide-induced hemodynamic and saluretic effects

European Journal of Clinical Pharmacology

Volumn 62, Issue 11, 2006, Pages 885-892

  Knauf, H ^a,d   Bailey, M A ^b   Hasenfuss, G ^c   Mutschler, E ^a,e  

^a University of Edinburgh ^*  (Germany)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d St Berward Krankenhaus   (Germany)

^e GOETHE UNIVERSITY   (Germany)

Author keywords

blockers; ACE inhibitors; AT1 receptor antagonists; Ca2+ channel blockers; NSAIDs; Thiazide diuretics; Tubuloglomerular feedback

Indexed keywords

AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIINFLAMMATORY AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM ION; CANDESARTAN; CARDIOVASCULAR AGENT; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROCHLOROTHIAZIDE; MAGNESIUM ION; PROPRANOLOL; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; SODIUM ION; THIAZIDE DIURETIC AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIURETIC ACTIVITY; DRUG ANTAGONISM; DRUG EFFECT; DRUG INHIBITION; DRUG POTENTIATION; FEMALE; GLOMERULUS FILTRATION RATE; HEMODYNAMICS; HUMAN; HUMAN EXPERIMENT; KIDNEY TUBULE ABSORPTION; MALE; MONOTHERAPY; NORMAL HUMAN; POTASSIUM EXCRETION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALURESIS; SODIUM EXCRETION;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR AGENTS; CROSS-OVER STUDIES; CYCLOOXYGENASE INHIBITORS; DIURETICS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ELECTROLYTES; FEEDBACK, BIOCHEMICAL; FEMALE; GLOMERULAR FILTRATION RATE; HEART FAILURE, CONGESTIVE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; NATRIURESIS; POTASSIUM;

EID: 33750448627     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-006-0190-3     Document Type: Article

References (48)

1. Schnermann J, Briggs JP (2000) Function of the juxtaglomerular apparatus: control of glomerular hemodynamics and renin secretion. In: Seldin DW, Giebisch G (eds) The Kidney: physiology and pathophysiology, 3rd edn. Lippincott and Wilkins, Philadelphia, pp 945-980
2. Cassin S, Vogh B (1966) Effect of hydrochlorothiazide on renal blood flow and clearance of para-amino-hippurate and creatinine. Proc Soc Exp Biol Med 122:970-973
3. Hropot M, Fowler N, Karlmark B, Giebisch G (1985) Tubular action of diuretics: distal effects on electrolyte transport and acidification. Kidney Int 28:477-489
4. Knauf H, Cawello W, Schmidt G, Mutschler E (1994) The saluretic effect of the thiazide-diuretic bemeticide in relation to the glomerular filtration rate. Eur J Clin Pharmacol 46:9-13
5. Okusa MD, Ellison DH (2000) Physiology and pathophysiology of diuretic action. In: Seldin DW, Giebisch G (eds) The Kidney: physiology and pathophysiology, 3rd edn. Lippincott and Wilkins, Philadelphia, pp 2877-2922
6. Friedman PA, Hebert SC (1997) Site and mechanism of diuretic action. In: Seldin D, Giebisch G (eds) Diuretic agents: clinical physiology and pathophysiology. Academic, New York, pp 75-113
7. Schlatter E (1993) Effects of various diuretics on membrane voltage of macula densa cells. Whole-cell-patch-clamp experiments. PflÏgers Arch 423:74-77
8. Greger RF (1995) Loop diuretics. In: Greger RF, Knauf H, Mutschler E (eds) Diuretics, Handb Exp Pharm 117. Springer, Berlin Heidelberg New York, pp 221-274
9. Braam B, Mitchell KD, Koomans HA, Navar LG (1993) Relevance of tubuloglomerular feedback mechanisms in pathophysiology. J Am Soc Nephrol 4:1257-1274
10. Knauf H Mutschler E (1990) Saluretic effects of the loop diuretic torasemide in chronic renal failure. Interdependence of electrolyte excretion. Eur J Clin Pharmacol 39:337-343
11. Navar LG (1997) Renal hemodynamic effects of diuretics. In: Seldin DW, Giebisch G (eds) Diuretic agents: clinical physiology and pharmacology. Academic, New York, pp 135-169
12. Vallon V (2003) Tubuloglomerular feedback and the control of glomerular filtration rate. News Physiol Sci 18:169-174
13. Leary WP, Reyes AJ, van der Byl K, Acosta-Barrios NT (1985) Effects of captopril, hydrochlorothiazide and their combination on timed urinary excretion of water and solutes. J Cardiovasc Pharmacol 7 (Suppl 1):56-62
14. Leary WP, Reyes AJ, van der Byl K (1992) Interactions between different diuretics and between diuretics and other drugs on renal excretion in man: mechanism and clinical implications. Prog Pharmacol Clin Pharmacol. 9:317-360
15. Cleland JGF (1997) Interaction between ACE inhibitors and diuretics. In: Seldin DW, Giebisch G (eds) Diuretic agents: clinical physiology and pharmacoloogy. Academic, New York, pp 321-334
16. Opie LH (1987) Calcium channel antagonists, part I: Fundamental properties: mechanisms, classification, sites of action. Cardiovasc Drugs Ther 1:411-430
17. Zanchetti A, Leonetti G (1990) Natriuretic effects of calcium antagonists. Clinical implications. Drugs 40 (Suppl 2):15-21
18. Epstein M (1991) Calcium antagonists and the kidney. Implications for renal protection. Am J Hypertension 4:482S-486S
19. Bauer JH, Reams GP (1987) Beta-adrenergic antagonists and the kidney. In: Brenner BM, Stein JH (eds) Pharmacotherapy of renal disease and hypertension. Churchill Livingstone, New York, pp 223-254
20. Leary WP, Reyes AJ, van der Byl K (1984) Effect of hydrochlorothiazide plus sotalol on urinary electrolyte excretion in normal subjects. S Afr Med J 66:680-681
21. Schrier RW (1988) Pathogenesis of sodium and water retention in high and low output cardiac failure, cirrhosis, nephrotic syndrome, and pregnancy. N Eng J Med 318:1065-1074
22. Seldin DW (1990) Sodium balance and fluid volume in normal and in edematous states. In: Seldin DW, Giebisch G (eds) The regulation of sodium and chloride balance. Raven, New York, pp 261-292
23. Skorecki KL, Brenner BM (1982) Body fluid homeostasis in congestive heart failure and cirrhosis with ascites. Am J Med 72:323-338
24. Better OS, Schrier RW (1983) Disturbed volume homeostasis in patients with cirrhosis of the liver. Kidney Int 23:303-311
25. Keller E, Hoppe-Seyler G, Schollmeyer P (1981) Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide. Eur J Clin Pharmacol 20:27-33
26. Kirchner KA (1997) Effect of prostaglandin inhibition on the action of diuretic agents. In: Seldin DW, Giebisch G (eds) Diuretic agents: clinical physiology and pharmacology. Academic, New York pp 247-258
27. Brater DC (1986) Drug-drug and drug-disease interactions with nonsteroidal anti-inflammatory drugs. Am J Med 80:(Suppl 1A) 62-77
28. Brater DC, Chennavasin P, Seiwell R (1980) Furosemide in patients with heart failure: shift in dose-response curve. Clin Pharmacol Ther 28:18-186
29. Chennavasin P, Seiwell R, Brater DC (1980) Pharmacokinetic-dynamic analysis of the indomethacin-furosemide interaction in man. J Pharmacol Exp Ther 215:66
30. MacGregor GA, Markandu ND, Banks RA et al (1982) Captopril in essential hypertension: Contrasting effects of adding hydrochlorothiazide or propranolol. Br Med J 284:693-696
31. Weinberger MH (1985) Blood pressure and metabolic responses to hydrochlorothiazide, captopril and the combination in black and white mild-to-moderate hypertensive patients. J Cardiovasc Pharmacol 7 (Suppl 1):S22-S25
32. MacGregor GA, Banks RA, Markandu ND, Bayliss J, Roulston J (1983) Lack of effect of beta-blocker on flat dose response to thiazide in hypertension: efficacy of low-dose thiazide combined with beta-blocker. BMJ 286:1535-1538
33. Cappuccio FP, Markandu ND, Singer DRJ, MacGregor GA (1993) Amlodipine and lisinopril in combination for the treatment of essential hypertension: efficacy and predictors of response. J Hypertens 11:839-847
34. Hansson L, Zanchetti A, Carruthers SG et al (1991) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised. Lancet 351:1755-1762
35. ALLHAT (2002) The antihypertensive and lipid-lowering treatment to prevent heart attack trial. Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 288:2981-2997
36. O'Connor CM, Bekin RN, Carson PE et al. for the PRAISE investigators (1995) Effect of amlodipine on mode of death in severe chronic heart failure. The PRAISE trial. Circulation 92 (Suppl):1-143
37. The CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure: results on the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 314:1547-1552
38. Pfeffer MA, Braunwald E, Moy L et al (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 327:669-677
39. The SOLVD Investigators (1992) Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327:685-691
40. Yusuf S, Pepine CJ, Garges L et al (1992) Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 340:1173-1178
41. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, Michelson EL, Olofsson B, Ústergren J, Yusuf S (2003) Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362:759-766
42. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, Michelson EL, Olofsson B, Ústergren J (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular efection fraction: the CHARM-Preserved Trial. Lancet 362:777-781
43. McMurray JJV, Ústergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362:767-771
44. Granger CB, McMurray JJV, Yusuf S, Held P, Michelson EL, Olofsson B, Ústergren J, Pfeffer MA, Swedberg K (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362:772-776
45. Waagstein F, Hjalmarson A, Varnaysclas E et al (1975) β-blockers in dilated cardiomyopathy. Br Heart J 37:1022-1036
46. Engemeier RS, O'Connel JB, Walsh R et al (1985) Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomised, placebo-controlled trial. Circulation 72:536-546
47. Packer M (1993) How should physicians view heart failure? The philosophical and physiological evolution of the conceptual models of the disease. Am J Cardiol 71:3C-11C
48. + excretion by furosemide and piretanide: role of bradykinin. J Am Soc Nephrol 15:876-884